MetaCap

Collegium Pharmaceutical (COLL) vs Pharming Group N.V. (PHAR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Pharming Group N.V. (PHAR) has outperformed Collegium Pharmaceutical (COLL) over the past year, losing 29.0% versus a loss of 45.2%. Over five years, PHAR leads with a +39.0% price change compared with +37.7% for COLL. Pharming Group N.V. is the larger company by market cap ($816.8 million vs $768.2 million), about 1.1 times the size.

On valuation, Collegium Pharmaceutical trades at a lower forward P/E (3.5x vs 64.1x for Pharming Group N.V.). Collegium Pharmaceutical converts more of its revenue into profit, with a net margin of 8.1% versus 0.8%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

COLL-45.24%PHAR-29.03%
+34%-11%-56%
Nov 21, 20251 yearNov 20, 2026
COLL+31.14%PHAR+33.87%
+174%+71%-31%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

COLL versus PHAR key metrics
MetricCOLLPHAR
Share price$24.72$11.54
Market cap$768.18M$816.78M
1-day change-1.94%-5.10%
YTD return-46.61%-34.69%
1-year return-45.24%-29.03%
5-year return+37.72%+39.04%
P/E ratio (TTM)22.6836.06
Forward P/E3.4964.11
EPS (TTM)$1.09$0.32
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$780.57M$376.13M
Revenue growth (YoY)+23.62%+26.56%
Net income (latest FY)$62.87M$2.85M
Gross margin59.35%87.90%
Operating margin23.01%6.87%
Net margin8.05%0.76%
52-week high$50.79$21.34
52-week low$21.43$9.11
Distance from 52-week high-51.33%-45.92%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+77.99%+209.36%
Average volume754.45K21.33K
Shares outstanding31.08M70.78M
Employees423407
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PHAR has outperformed COLL by 16.2 percentage points over the past year.
  • Pharming Group N.V. trades at a higher earnings multiple (36.1x vs 22.7x trailing P/E).
  • Collegium Pharmaceutical is more profitable, keeping 8.1 cents of every revenue dollar as net income versus 0.8 cents for Pharming Group N.V..

About Collegium Pharmaceutical

COLL stock →

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.

Health Care · Biotechnology: Pharmaceutical Preparations · 423 employees

About Pharming Group N.V.

PHAR stock →

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kd inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Health Care · Biotechnology: Pharmaceutical Preparations · 407 employees

COLL vs PHAR FAQ

Which is bigger, Collegium Pharmaceutical or Pharming Group N.V.?

Pharming Group N.V. (PHAR) is larger, with a market capitalization of $816.78M compared with $768.18M for Collegium Pharmaceutical (COLL).

Which stock has performed better over the past year, COLL or PHAR?

PHAR returned -29.03% over the past 12 months, compared with -45.24% for COLL (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, COLL or PHAR?

COLL has the lower trailing P/E at 22.7, versus 36.1 for PHAR. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Are Collegium Pharmaceutical and Pharming Group N.V. in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons